A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study)

医学 止吐药 化疗引起恶心呕吐 恶心 奥氮平 呕吐 消炎药 安慰剂 化疗 干呕 养生 昂丹司琼 临床终点 化疗方案 麻醉 内科学 随机对照试验 精神科 精神分裂症(面向对象编程) 替代医学 病理
作者
Yuanyuan Zhao,Yunpeng Yang,Fangfang Gao,Chang-Lu Hu,Diansheng Zhong,Miaozhen Lu,Zhiping Yuan,Jianqing Zhao,Jidong Miao,Yán Li,Jie Zhu,Chunbin Wang,Jianjun Han,Yanqiu Zhao,Yan Huang,Li Zhang
出处
期刊:EClinicalMedicine [Elsevier BV]
卷期号:55: 101771-101771 被引量:23
标识
DOI:10.1016/j.eclinm.2022.101771
摘要

BackgroundEvidence supports prophylactic use of olanzapine for the treatment of chemotherapy-induced nausea and vomiting (CINV). However, most studies to date have focused on patients with single-day highly emetogenic chemotherapy (HEC). Currently, administration of antiemetic therapies for nausea and vomiting induced by multiday chemotherapy regimens remains a challenge. In this study, we evaluated the efficacy of olanzapine combined with triple antiemetic therapy for the prevention of CINV in patients receiving multiday chemotherapy.MethodsWe performed a randomized, double-blind, placebo-controlled phase 3 trial in 22 hospitals. Eligible patients were between 18 and 75 years old, were diagnosed with malignant solid tumors, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2. All the study participants were scheduled to be treated with chemotherapy regimens containing 3-day cisplatin (3-day total dose ≥75 mg/m2). Randomization was computer generated and stratified by gender and chemotherapy treatment history. Allocation was done via an interactive web response system. Enrolled patients were randomly assigned 1:1 to receive either 5 mg olanzapine or placebo orally before bedtime for 5 days combined with intravenous fosaprepitant (150 mg) 1 h before the administration of cisplatin on day 1, ondansetron hydrochloride intravenously, and dexamethasone orally 30 min before cisplatin from days 1 to 3. Dexamethasone was also administered at the same time on days 4 and 5. The primary endpoint was the proportion of subjects with complete response (no vomiting and no rescue therapy) within the overall phase (days 1–8) after starting chemotherapy. Baseline plasma concentrations of P-substance and 5-HT were measured for exploratory analysis. This study was registered at ClinicalTrials.gov, number NCT04536558.FindingsBetween December 2020 and September 2021, 349 patients with malignant solid tumors were enrolled in the study, with 175 participants randomly assigned to receive olanzapine and 174 participants assigned to receive placebo. The proportion of patients who achieved a complete response in the overall phase was significantly higher in the olanzapine group than in the placebo group (69% vs. 58%, P = 0.031). A complete response benefit was observed in the olanzapine group versus the placebo group in almost all the subgroups. Four factors were considered significantly associated with complete response in multivariable analysis: treatment group, gender, baseline plasma concentration of 5-HT, and prior radiotherapy. All the reported adverse events associated with olanzapine administration were grades 1 and 2.InterpretationOlanzapine (5 mg) combined with fosaprepitant, ondansetron, and dexamethasone was better than triple antiemetic therapy alone for patients receiving multiday chemotherapy regimens. Based on these results, the four-drug combination should be recommended as the best antiemetic regimen given to patients receiving multiday cisplatin-based chemotherapy and baseline plasma concentration of 5-HT may be used to identify individuals who are prone to CINV. However, all these findings need to be further validated in future studies.FundingJiangsu Hansoh Pharmaceutical Group Co., Ltd. provided research grant and study drugs for this investigator-initiated study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
赘婿应助温柔初珍采纳,获得10
刚刚
SYLH应助张真狗采纳,获得10
1秒前
1秒前
1秒前
2秒前
科研通AI2S应助暴躁的阁采纳,获得10
3秒前
3秒前
紧张的芷完成签到,获得积分10
3秒前
量子星尘发布了新的文献求助10
5秒前
赘婿应助ldx采纳,获得10
5秒前
婷婷发布了新的文献求助10
5秒前
慕烊琪发布了新的文献求助10
5秒前
Jacky77完成签到,获得积分10
5秒前
热心市民小红花应助MAKEYF采纳,获得10
7秒前
AiX-zzzzz发布了新的文献求助10
7秒前
shuqi完成签到 ,获得积分10
7秒前
8秒前
高梦雪完成签到,获得积分10
8秒前
研友_Z3vbRn应助hhh采纳,获得10
8秒前
申申来啦完成签到,获得积分10
8秒前
哈哈哈完成签到,获得积分10
8秒前
9秒前
9秒前
9秒前
10秒前
yyd完成签到 ,获得积分10
10秒前
setuin发布了新的文献求助10
10秒前
LQH发布了新的文献求助10
11秒前
BlueBlue发布了新的文献求助20
11秒前
焜少完成签到,获得积分10
11秒前
夕诙完成签到,获得积分0
12秒前
14秒前
iFaceDOG发布了新的文献求助10
14秒前
15秒前
momoyu完成签到,获得积分10
15秒前
Ava应助yuer采纳,获得10
16秒前
16秒前
一切随风发布了新的文献求助10
18秒前
深情安青应助日月日月采纳,获得10
18秒前
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970172
求助须知:如何正确求助?哪些是违规求助? 3514982
关于积分的说明 11176568
捐赠科研通 3250212
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875702
科研通“疑难数据库(出版商)”最低求助积分说明 805004